[go: up one dir, main page]

SI1165049T1 - Aglomerati s kristalizacijo - Google Patents

Aglomerati s kristalizacijo

Info

Publication number
SI1165049T1
SI1165049T1 SI200030366T SI200030366T SI1165049T1 SI 1165049 T1 SI1165049 T1 SI 1165049T1 SI 200030366 T SI200030366 T SI 200030366T SI 200030366 T SI200030366 T SI 200030366T SI 1165049 T1 SI1165049 T1 SI 1165049T1
Authority
SI
Slovenia
Prior art keywords
agglomerates
crystallisation
lactum
solvents
suspension
Prior art date
Application number
SI200030366T
Other languages
English (en)
Other versions
SI1165049T2 (sl
Inventor
Johannes Booij
Ageeth Geertruida Lefferts
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1165049(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Publication of SI1165049T1 publication Critical patent/SI1165049T1/sl
Publication of SI1165049T2 publication Critical patent/SI1165049T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
SI200030366T 1999-04-01 2000-04-03 Aglomerati s kristalizacijo SI1165049T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99201034 1999-04-01
EP00917035A EP1165049B2 (en) 1999-04-01 2000-04-03 Agglomerates by crystallisation
PCT/EP2000/002917 WO2000041478A2 (en) 1999-04-01 2000-04-03 Agglomerates by crystallisation

Publications (2)

Publication Number Publication Date
SI1165049T1 true SI1165049T1 (sl) 2004-12-31
SI1165049T2 SI1165049T2 (sl) 2011-11-30

Family

ID=8240058

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030366T SI1165049T2 (sl) 1999-04-01 2000-04-03 Aglomerati s kristalizacijo

Country Status (12)

Country Link
US (3) US6979735B1 (sl)
EP (1) EP1165049B2 (sl)
CN (1) CN1209099C (sl)
AT (1) ATE260096T1 (sl)
AU (1) AU3817300A (sl)
CA (1) CA2364342C (sl)
DE (1) DE60008508T9 (sl)
ES (1) ES2215628T5 (sl)
MX (1) MXPA01009808A (sl)
SI (1) SI1165049T2 (sl)
TR (1) TR200102771T2 (sl)
WO (1) WO2000041478A2 (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
EP1330236A2 (en) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
EP1328528B1 (en) * 2000-10-20 2004-12-29 Sandoz Ag Pharmaceutical compositions comprising clavulanic acid
GB0031267D0 (en) * 2000-12-21 2001-01-31 Smithkline Beecham Plc Novel compositions
WO2002083129A2 (en) * 2001-04-12 2002-10-24 Sandoz Gmbh Pharmaceutical composition comprising clavulanic acid
AT500131A1 (de) * 2002-02-01 2005-11-15 Sandoz Ag Organische verbindungen
AT500134A1 (de) * 2002-02-01 2005-11-15 Sandoz Ag Verfahren zur herstellung eines entmischungsstabilen granulats
AT500132A1 (de) * 2002-02-06 2005-11-15 Sandoz Ag Organische verbindungen
AT500133A1 (de) * 2002-02-06 2005-11-15 Sandoz Ag Verfahren zur herstellung eines entmischungsstabilen granulats
JP4949827B2 (ja) * 2003-03-21 2012-06-13 ディーエスエム アイピー アセッツ ビー．ブイ． アモキシシリン三水和物
US7534781B2 (en) 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
AU2005204017B2 (en) * 2004-01-06 2008-01-31 Panacea Biotec Ltd. Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer
WO2016109555A1 (en) 2014-12-29 2016-07-07 Bioventus, Llc Systems and methods for improved delivery of osteoinductive molecules in bone repair
CN108905264A (zh) * 2018-07-17 2018-11-30 凯莱英医药集团（天津）股份有限公司 连续化结晶方法在β-内酰胺类抗生素合成中的应用及连续化结晶系统
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697506A (en) * 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3692781A (en) * 1971-02-26 1972-09-19 Glaxo Lab Ltd Recovery of pure cephalexin from acidic reaction mixtures
US4138555A (en) * 1971-05-14 1979-02-06 Glaxo Laboratories, Limited (6R,7R)-7-[2-aryl-2-(etherified oximino)acetamido]-3-carbamoyloxymethylceph-3-em-4-carboxylic acid 1-oxides
AR206201A1 (es) * 1972-06-29 1976-07-07 Ciba Geigy Ag Procedimiento para la obtencion de compuestos de acido 7beta-amino-3-cefem-3-01-4-carboxilico0-substituidos
US3932386A (en) * 1973-06-18 1976-01-13 American Home Products Corporation Sodium 6-(L-aminocyclohexane carboxamido)penicillanic acid
GB1563103A (en) * 1975-10-13 1980-03-19 Beecham Group Ltd Process for the preparation of clavulanic acid
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
US4454069A (en) * 1979-08-24 1984-06-12 Beecham Group Limited Clavulanic acid salts and their preparation from the tertiary butyl amine salt
NZ199061A (en) * 1980-12-09 1984-10-19 Beecham Group Ltd 9-(n-tetrazolyl)-deoxyclavulanic acids,salts,esters,and pharmaceutical compositions
US4522701A (en) * 1982-02-11 1985-06-11 E. I. Du Pont De Nemours And Company Process for preparing an anisotropic aromatic pitch
US4456753A (en) 1983-02-07 1984-06-26 Pfizer Inc. Process for the manufacture of highly crystalline sodium cefoperazone
DE3314725A1 (de) * 1983-04-22 1984-10-25 Siemens AG, 1000 Berlin und 8000 München Oberflaechenwellen-resonatorfilter
US4659812A (en) * 1985-08-20 1987-04-21 Bristol-Myers Company Cephalosporin intermediates
GB8608962D0 (en) * 1986-04-12 1986-05-14 Beecham Group Plc Beta-lactam antibiotics
NZ223316A (en) 1987-01-29 1989-10-27 Beecham Group Plc Crystalline potassium clavulanate and pharmaceutical compositions
US5288861A (en) * 1987-01-29 1994-02-22 Beecham Group Plc Potassium clavulanate in rosette form
WO1991000865A1 (en) 1989-07-10 1991-01-24 Gema S.A. A novel stable form of cephradine, process for its production and intermediates used therein
GB9009473D0 (en) 1990-04-27 1990-06-20 Beecham Group Plc Pharmaceutical formulation
US5250525A (en) * 1991-02-12 1993-10-05 Pliva Handels Gmbh 4-oxo-azetidine-2-sulfonic acids and their salts, processes for the preparation thereof and their use
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
AT400033B (de) * 1992-03-10 1995-09-25 Biochemie Gmbh Neues verfahren zur isolierung und reinigung von clavulansäure und zur herstellung von pharmakologisch verträglichen salzen derselben
AT401871B (de) † 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
SI9400107A (en) * 1994-03-02 1995-10-31 Lek Tovarna Farmacevtskih New process of the isolation of clavulanic acid and its pharmaceutical salts from fermented broth of streptomyces sp.p 6621 ferm p 2804.
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE4426973C1 (de) * 1994-07-29 1996-03-28 Degussa Verfahren zur Herstellung eines als Brennstoffzellenelektrode einsetzbaren Plattinlegierungskatalysators
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
ZA975198B (en) 1996-06-13 1997-12-15 Smithkline Beecham Corp Improved process for preparing potassium clavulanate.
AU4011397A (en) † 1996-07-16 1998-02-09 Gist-Brocades B.V. Beta-lactam granules free of organic solvents
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
AU5551698A (en) 1996-11-11 1998-06-03 Gist-Brocades B.V. Process for the preparation of salts and esters of clavulanic acid
EP0867515B1 (en) * 1997-03-24 1999-12-08 CIPAN-Companhia Industrial Produtora De Antibioticos, S.A. Process for the isolation of a pharmaceutically acceptable alkali metal salt of clavulanic acid
EP1023065A1 (en) 1997-08-29 2000-08-02 Dsm N.V. Granules free of excipients

Also Published As

Publication number Publication date
WO2000041478A2 (en) 2000-07-20
SI1165049T2 (sl) 2011-11-30
US20060079496A1 (en) 2006-04-13
TR200102771T2 (tr) 2002-04-22
EP1165049B1 (en) 2004-02-25
ES2215628T3 (es) 2004-10-16
CA2364342A1 (en) 2000-07-20
CN1345231A (zh) 2002-04-17
US6979735B1 (en) 2005-12-27
WO2000041478A3 (en) 2000-11-02
DE60008508T2 (de) 2004-12-23
US20110045082A1 (en) 2011-02-24
CA2364342C (en) 2011-02-01
MXPA01009808A (es) 2002-04-24
ES2215628T5 (es) 2011-11-28
EP1165049A2 (en) 2002-01-02
DE60008508T9 (de) 2012-06-14
ATE260096T1 (de) 2004-03-15
EP1165049B2 (en) 2011-07-06
AU3817300A (en) 2000-08-01
DE60008508T3 (de) 2012-01-19
DE60008508D1 (de) 2004-04-01
CN1209099C (zh) 2005-07-06

Similar Documents

Publication Publication Date Title
SI1165049T1 (sl) Aglomerati s kristalizacijo
AU626699B2 (en) Substituted quinazolinones as angiotensin ii antagonists
WO1997047270A3 (en) Novel anti-viral compounds
NZ519241A (en) Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
IL101012A0 (en) Pyranyl cyanoguanadine derivatives,processes for the preparation thereof and cardioplegic solution containing the same
HUT37794A (en) Process for producing new beta-carbolina-3-oxa-diazolyl derivatives and pharmaceutical compositions containing them
CA2283507A1 (en) Process for preparing pyrazole derivatives
HU912649D0 (en) New tricyclic compounds production threreof and anti-microbic preparatives
WO2002092602A3 (en) PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-[2,3-f] QUINOLINE
WO2003029254A1 (fr) Procede de preparation de composes tricycliques
NZ501896A (en) Process for producing isoxazolidinedione compound
AU6578400A (en) Novel method for preparing benzoperhydroisoindole compounds
WO2002016322A3 (en) Process for the preparation of 2-aminoethylpyridines
WO2002072567A3 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU4621500A (en) Novel aluminosiloxane compound and process for preparing the same
CA2164918A1 (en) Thiol compounds
CA2294147A1 (en) Process for the production of methyl methacrylate
YU27099A (sh) Postupak i intermedijari za proizvodnju piridin-2,3- dikarboksilat jedinjenja
WO1998034584A3 (en) Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
CA2174797A1 (en) Cyanobenzenesulfenyl halide and process for preparation of 3-substituted benzisothiazole using the same
AU9462298A (en) Process for producing 3-cephem compounds
CA2366600A1 (en) A process for the preparation of 1,4,7,10-tetraazacyclododecane
TWI255812B (en) A process for the preparation of r-(+)-6-carboxamido-3-n-methylamino-1,2,3,4-tetrahydrocarbazole
WO2004031153A3 (en) Enantioselective alkylation of tricyclic compounds
AU2001256253A1 (en) Chemical process